A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of Gastrointestinal or Colorectal Cancer

Trial Profile

A Phase 3 Randomized Placebo-controlled Double-blind Study of Romiplostim for the Treatment of Chemotherapy-induced Thrombocytopenia in Patients Receiving FOLFOX-based Chemotherapy for Treatment of Gastrointestinal or Colorectal Cancer

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Romiplostim (Primary)
  • Indications Thrombocytopenia
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 09 Apr 2018 Planned End Date changed from 26 Aug 2021 to 25 Aug 2021.
    • 09 Apr 2018 Planned primary completion date changed from 26 Aug 2021 to 25 Aug 2021.
    • 09 Apr 2018 Planned initiation date changed from 8 Sep 2018 to 7 Sep 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top